Suresh Ramalingam, MD | Authors

Articles

CheckMate 227 Induced Manageable Toxicities With Immunotherapy Combination in NSCLC

June 26, 2020

Suresh Ramalingam, MD, FASCO, discusses the key takeaways regarding the toxicities observed in the phase 3 CheckMate 227 clinical trial, which evaluated immunotherapeutic agents nivolumab plus ipilimumab as treatment of patients with non–small cell lung cancer.

Dr. Suresh Ramalingam on Immune Checkpoint Inhibitors in NSCLC Treatment

November 20, 2015

Dr. Suresh Ramalingam on sequencing immune checkpoint inhibitors with chemotherapy in NSCLC treatment. He adds that a new class of agents can be given in conjunction with immune checkpoint inhibitors, such as IDO inhibitors.